Table 3.
Summary of Exposure to Allopurinol and Safety Blood Tests at Each Study Visit
| Variable | Laboratory Reference Range | Baseline | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 |
|---|---|---|---|---|---|---|---|
| Expected cumulative allopurinol exposure per patient (mg) | Not applicable | 0 | 300 | 900 | 1650 | 2550 | 3600 |
| Expected number of doses of allopurinol per patient | Not applicable | 0 | 3 | 6 | 9 | 12 | 15 |
| White cell count (cells/mm3) | 4000–11 000 | 7630 ± 2894 | 7350 ± 2690 | 7750 ± 2577 | 7840 ± 2768 | 8250(IQR 7050–8900) | 7820 ± 3111 |
| Hemoglobin (g/dL) | 13–18 | 12.0 ± 1.2 | 11.2 ± 0.9 | 11.4 ± 1.0 | 11.1 ± 0.9 | 11.1 ± 0.6 | 10.9 ± 0.5 |
| Albumin (g/dL) | 3.5–5.0 | 3.3 ± 0.4 | 3.4 ± 0.4 | 3.4 ± 0.4 | 3.3 ± 0.4 | 3.3 ± 0.5 | 3.3 ± 0.5 |
| Bilirubin (mg/dL) | 0–1.2 | 0.3 (IQR 0.2–0.4) | 0.3 (IQR 0.2–0.4) | 0.2 (IQR 0.2–0.3) | 0.3 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.2 |
| Alkaline phosphatase (U/L) | 30–130 | 117 ± 64 | 107 ± 50 | 102 ± 42 | 99 ± 39 | 104 ± 45 | 86 (IQR 74–93) |
| Alanine aminotransferase (U/mL) | 5–55 | 18.2 ± 5.7 | 17.8 ± 6.1 | 16.9 ± 5.2 | 17.8 ± 6.1 | 18.1 ± 6.1 | 17.9 ± 7.7 |
| Phosphate (mg/dL) | 2.5–4.6 | 5.6 ± 0.6 | 5.9 ± 1.2 | 5.6 ± 0.9 | 5.6 ± 0.9 | 5.6 ± 1.2 | 5.6 ± 0.9 |
| Potassium (mmol/L) | 3.5–5.3 | 5.3 ± 0.6 | 5.2 ± 0.5 | 5.2 ± 0.7 | 5.2 ± 0.5 | 5.4 ± 0.6 | 5.3 ± 0.5 |
Data is presented as mean ± standard deviation or median (IQR 1–3). IQR, interquartile range.